Cartel damages - BarentsKrans

Search

Expertise

Arbitration Commercial Contracts Commercial Litigation Corporate / M&A Corporate Litigation

Sectors

Agri & Food Energy & Renewables Healthcare Hospitality & Leisure Life Sciences

Special Topics

Cartel Damages Environmental, Social and Corporate governance (ESG) Mass Litigation

Specialists

Hanine Al-Nassar

Hanine Al-Nassar

Attorney-at-Law

Nuray Aslan

Nuray Aslan

Associate Attorney-at-Law

Remco Bäcker

Remco Bäcker

Attorney-at-Law Partner

Insights

November 30, 2023

Corporate / M&A Mergers & Acquisitions

BarentsKrans advised sellers on sale Incore Software

Incore Software sells 100% of its shares to ICT Group. Harry Rek and Thomas van Hövell tot Westervlier advised Incore on the sale.

November 8, 2023

BarentsKrans’ Cartel Damages team contributes to ICLG Competition Litigation 2024 edition

The Netherlands is one of the most prominent European jurisdictions for private enforcement (cartels and abuse of dominance). Our Cartel Damages team, wrote the Dutch chapter for the 2024 edition of the International Comparative Legal Guide - Competition Litigation.

October 1, 2023

Data & Privacy IP & Technology

Substantial expansion of IP, Data & Technology practice as Marc Elshof and team join BarentsKrans

Welcoming Marc Elshof to the firm on 1 October 2023, BarentsKrans will gain a new partner with extensive experience in the field of technology, data and privacy. Anouschka van de Graaf, Job Julicher and Julius Louter are also switching to BarentsKrans.

September 12, 2023

IP & Technology Life Sciences Patents & Technology Pharma & Regulatory

Pharma Alert | Apixaban decision overturned on appeal: injunction granted

By judgment of 15 August 2023 in PI proceedings brought by Bristol-Myers Squibb, the Court of Appeal of The Hague prohibited Sandoz, Stada and Teva from marketing generic apixaban.